BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

With a cleaner safety profile and better efficacy than marketed agents, Regeneron’s first-in-class evinacumab is poised to become the standard of care for homozygous familial hypercholesterolemia and other rare lipid disorders, including for the hardest...
BioCentury | Sep 1, 2018
Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BioCentury | Aug 31, 2018
Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

Mabpharm Ltd. (Taizhou, China) proposed Aug. 22 to list on the Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by CICC. Mabpharm is the second biotechnology company this week to file to...
BioCentury | Aug 22, 2018
Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

Mabpharm Ltd. (Taizhou, China) proposed Wednesday to list on the Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by CICC. Mabpharm is the second biotechnology company this week to file to list...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Sep 29, 2017
Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
BioCentury | Sep 25, 2017
Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
BioCentury | Mar 25, 2017
Strategy

Risky business

Amgen Inc. ’s proposal to increase access to cholesterol drug Repatha evolocumab will hinge on increasing medication adherence rates. In addition to continuing its existing adherence programs that use electronic alerts, the biotech hopes to...
BioCentury | Mar 17, 2017
Company News

Familial Hypercholesterolemia, Express Scripts news

The foundation said it partnered with Express Scripts to expand the PBM’s coverage of familial hypercholesterolemia patients, giving them broader access to PCSK9 inhibitors. Under the PBM's new criteria, patients would qualify for prior authorization...
BioCentury | Mar 15, 2017
Company News

Express Scripts expanding PCSK9 coverage for FH patients

The Familial Hypercholesterolemia Foundation (Pasadena, Calif.) said it partnered with Express Scripts Holding Co. (NASDAQ:ESRX) to expand the PBM’s coverage of familial hypercholesterolemia patients, giving them broader access to PCSK9 inhibitors. Under the PBM's new...
Items per page:
1 - 10 of 116